异基因移植：骨髓纤维化、慢性粒单核细胞白血病及费城染色体阴性/BCR-ABL阴性慢性粒细胞白血病的一种治疗选择。
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
作者信息
Mittal P, Saliba R M, Giralt S A, Shahjahan M, Cohen A I, Karandish S, Onida F, Beran M, Champlin R E, de Lima M
机构信息
Department of Blood and Marrow Transplant, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
出版信息
Bone Marrow Transplant. 2004 May;33(10):1005-9. doi: 10.1038/sj.bmt.1704472.
The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n=5), chronic myelomonocytic leukemia (CMML) (n=8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n=7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%-67%), and disease-free survival 37% (95% CI 17-58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.
异基因移植在除慢性髓性白血病之外的骨髓增殖性疾病中的作用尚未明确。在我们机构，共有20例中位年龄为51岁的患者接受了异基因造血干细胞移植（HSCT），其中5例为骨髓纤维化、8例为慢性粒单核细胞白血病（CMML）、7例为费城（Ph）染色体阴性/BCR-ABL阴性慢性髓性白血病（CML）。在HSCT前发生急性白血病的患者被排除在本分析之外。共有15例患者接受了亲属供体移植，5例接受了非亲属供体移植。1例患者植入失败。中位随访17.5个月后，2年实际生存率为47%（95%CI 2%-67%），无病生存率为37%（95%CI 17-58%）。异基因移植可能为骨髓纤维化、CMML和Ph染色体阴性/BCR-ABL阴性CML患者提供一种治疗选择。
Zotero 插件